Interpace Biosciences Inc (IDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Sales | 134,589 | 80,384 | 105,233 | 117,131 | 239,242 |
| Cost of Goods | 108,037 | 55,844 | 103,126 | 85,516 | 183,398 |
| Gross Profit | 26,552 | 24,540 | 2,107 | 31,615 | 55,844 |
| Operating Expenses | 33,492 | 60,504 | 35,553 | 46,411 | 50,329 |
| Operating Income | -6,903 | -35,120 | -33,320 | -14,280 | 5,913 |
| Other Income | 120 | 208 | 2,839 | 6,073 | 4,738 |
| Pre-tax Income | -6,783 | -34,912 | -30,481 | -8,207 | 10,651 |
| Income Tax | 392 | -6,838 | 871 | 1,767 | -724 |
| Net Income Continuous | -7,175 | -28,074 | -31,352 | -9,974 | 11,375 |
| Net Income Discontinuous | 361 | -5,486 | -3,109 | N/A | 434 |
| Net Income | $-6,814 | $-33,560 | $-34,461 | $-9,974 | $11,809 |
| EPS Basic Total Ops | -48.00 | -236.00 | -242.00 | -70.00 | 85.00 |
| EPS Basic Continuous Ops | -50.00 | -197.00 | -220.00 | -70.49 | 82.00 |
| EPS Basic Discontinuous Ops | 2.00 | -39.00 | -22.00 | N/A | 3.00 |
| EPS Diluted Total Ops | -48.00 | -236.00 | -242.00 | -70.00 | 84.00 |
| EPS Diluted Continuous Ops | -50.00 | -197.00 | -220.00 | -70.49 | 81.00 |
| EPS Diluted Discontinuous Ops | 2.00 | -39.00 | -22.00 | N/A | 3.00 |
| EBITDA(a) | $-5,074 | $-32,282 | $-28,707 | $-8,673 | $11,677 |